Skip to main content
HCM logo

HUTCHMED (China) Limited (HCM) Stock: Price, Forecast & Analyst Target

HUTCHMED (China) Limited (HCM) — MoonshotScore 70/100 (Strong band), calculated Nov 18, 2026. Price $13.22 (-1.71%), as of the Nov 20, 2026 trading session; market cap $2.30B.

Educational signal · not a buy or sell recommendation · How to read this

$13.22 −$0.23 (-1.71%) Market Cap $2.30B

HUTCHMED (China) Limited · HCM · NASDAQ

HUTCHMED (China) Limited is a biopharmaceutical company focused on discovering, developing, and commercializing innovative targeted and immune-based treatments for various cancers and immunological disorders. The company maintains a robust pipeline of therapeutic candidates and strategic collaborations, operating globally from its Hong Kong headquarters.

Price as of Nov 20, 2026

Key Statistics

70 of 100

MoonshotScore v2 · HUTCHMED (China) (HCM)

Strong
Business Quality Average (57)
Financial Safety Fortress (84)
Valuation Full (54)
Growth Durability Flat (52)
Momentum Surging (83)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $139M (Q2 FY2026, quarter ended Jun 30, 2026)
  • Altman Z 4.18 · Piotroski F 6
  • ROE 1.5% · ROA -1.2% · current ratio 5.64

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HCM (53 recorded, newest six shown)
RecordedScoreBand
71Strong
74Strong
74Strong
70Strong
70Strong
70Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$13.22
Change on the day-1.71%
52-week range$9.77 – $16.33
Market capitalisation$2.30B—
Price / earnings (trailing)149.78
Shares traded on the day32.8K

Price & events

Other perspectives

Council score for HUTCHMED (China) (HCM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Strong
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Weak
Gross Margin Weak

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is HUTCHMED (China) (HCM), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. HUTCHMED (China) Limited (HCM) is listed on NASDAQ. It employs 1,796 people and is led by Chig Fung Cheng. In Q2 FY2026 it reported revenue of $139M and net income of $8M. The market values it at $2.30B.

2 · Latest results

What do the latest results show for HUTCHMED (China) (HCM)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $139M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$139M$8M$0.05 (diluted)
Q1 FY2026$139M$8M$0.05 (diluted)
Q4 FY2025$135M$977,500$0.01 (diluted)
Q3 FY2025$135M$977,500$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for HUTCHMED (China) (HCM)?

Short answer

The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 4.18 · Piotroski F 6. Trailing ratios: ROE 1.5% · ROA -1.2% · current ratio 5.64.

4 · What to check next?

What should you watch next at HUTCHMED (China) (HCM)?

Short answer · as of

Current published price targets run low $13.60 · high $45.00 · consensus $22.78 · median $16.25 against a quoted price of $13.22 (as of Nov 20, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does HUTCHMED (China) compare with its peers?

Short answer

HUTCHMED (China)'s score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Named competitor$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.10 Nov 20, 2026$6.68B96 5-pillar Nov 18, 2026
Cronos Group Inc. (CRON) Same industry, near in market value$3.04 Nov 20, 2026$1.11B95 5-pillar Nov 18, 2026
ANI Pharmaceuticals, Inc. (ANIP) Same industry, near in market value$68.55 Nov 20, 2026$1.56B94 5-pillar Nov 18, 2026
Pacira BioSciences, Inc. (PCRX) Same industry, near in market value$36.48 Nov 20, 2026$1.46B92 5-pillar Nov 18, 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Same industry, near in market value$28.11 Nov 19, 2026$1.20B86 5-pillar Nov 18, 2026
Phibro Animal Health Corporation (PAHC) Same industry, near in market value$33.29 Nov 20, 2026$1.35B78 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.61 Nov 20, 2026$5.94B74 5-pillar Nov 18, 2026
HUTCHMED (China) (HCM) — this page$13.22$2.30B70
Collegium Pharmaceutical, Inc. (COLL) Same industry, near in market value$25.21 Nov 19, 2026$783M58 5-pillar Nov 18, 2026
Regencell Bioscience Holdings Limited (RGC) Same industry, near in market value$4.18 Nov 20, 2026$2.07B47 5-pillar Nov 18, 2026
Harrow Health, Inc. (HROW) Same industry, near in market value$30.41 Nov 20, 2026$1.14B33 5-pillar Nov 18, 2026
Bausch Health Companies Inc. (BHC) Same industry, near in market value$8.22 Nov 20, 2026$3.08B30 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$13.60 – $45.00
Consensus target
$22.78
Median target
$16.25

Consensus record · Captured .

Measured against a quoted price of $13.22 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
8
Identified insiders
4
Purchases
0
Sales
0
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HCM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported HCM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about HUTCHMED (China) (HCM)?

Read these with our analysis →

Common Questions About HCM

These answers are editorial: 1 of these 9 answers is drawn from the HCM research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for HCM?

HCM carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is HCM a good stock to buy?

Stock Expert AI does not rate HCM buy, sell or hold. HUTCHMED (China) Limited carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the HCM stock price today?

The last price recorded for HUTCHMED (China) Limited (HCM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the HCM price target?

The analyst consensus price target for HUTCHMED (China) Limited (HCM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for HCM?

The main risks for HUTCHMED (China) Limited are inherent to the biopharmaceutical industry. A primary concern is the high rate of clinical trial failures, where pipeline candidates may not demonstrate sufficient efficacy or safety, leading to significant financial losses and delays.

What are the key factors to evaluate for HCM?

HUTCHMED (China) Limited (HCM) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. NETs, for instance, represent a niche but growing market with specific treatment challenges. Not financial advice.

How frequently does HCM data refresh on this page?

HCM's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven HCM's recent stock price performance?

HUTCHMED (China) Limited (HCM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive and diversified pipeline of targeted and immune-based therapies for oncology and immunology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider HCM overvalued or undervalued right now?

The trailing P/E of HUTCHMED (China) Limited (HCM) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 13 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.